

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Markku Anttila, et al.

Appln. No.: 10/777,211

Filed: February 13, 2004

For: METHOD FOR ENHANCING
THE BIOAVAILABILITY OF
OSPEMIFENE

Attorney Docket No: 13601-72

Examiner: Shirley V. Gembeh

Art Unit: 1614

Confirmation No.: 2487

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 CFR §1.56 and §§1.97-1.98, and more particularly in accordance with 37 CFR §1.97(c), Applicant hereby cites the following reference(s):

U.S. PATENT DOCUMENTS		
DOCUMENT NO.	DATE	NAME
US 6,219,674	04/17/2001	Classen
US 6,584,472	06/24/2003	Classen
US 6,653,639	01/26/2006	Classen
US 5,912,273	06/15/1999	Degregorio, et al.
US 5,605,700	02/25/1997	Degregorio, et al.
US 2005/0187301 A1	08/25/2005	Lehtola, et al.
US 2007/0104742 A1	05/10/2007	Lehtola, et al.
US 2005/0272825A1	12/5/2005	Blom, et al.
US 2005/0187302 A1	08/25/2005	Blom, et al.

FOREIGN PATENT DOCUMENTS		
DOCUMENT NO.	DATE	COUNTRY
EP 1 713 458 B1	10/25/2006	Europe

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 CFR §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary, 37

C.F.R. §1.98(a)(3). Applicant respectfully requests the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 CFR §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 CFR §1.56(a).

Applicant has calculated a processing fee in the amount of \$180.00 to be due under 37 CFR §1.17(p) in connection with the filing of this Information Disclosure Statement. Applicant has enclosed a check covering this fee, or authorized charging the fee to a deposit account or credit card, as indicated in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

April 30, 2010

Date

William R. Boudreaux/

William R. Boudreaux

(Reg. No. 35,796)